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growth factor, even though it is a mitogen for mesenchymal cells too) could be important in breast development as it stimulated growth of mouse mammary gland explants. The role of EGFR was later proved by showing impaired mammary gland development in mice harbouring EGFR mutations (Cohen, 1997) .
Structure and function
Erb-B (ligand-receptor) layer, an intermediate signalling core processing cellular responses (Citri and Yarden, 2006) .
All Erb-B receptors consist of an extracellular domain which binds ligands (except in the case of Erb-B2), a transmembrane region and a cytoplasmic domain with kinase activity. Although there are 10 possible combinations of Erb-B dimers, not all are fully biologically active. Erb-B2 has no known ligands, but is the preferred partner of all family members, due to an intrinsically extended interaction loop rendering it constitutively available for dimerisation. Erb-B2 can stabilise EGFR in a conformation that potentiates dimerisation and phosphorylation in the absence of ligand and alters endotransactivation of EGFR can be achieved by ligand-independent intracellular mechanisms, such as G protein-coupled receptor (GPCR) stimulation of Src or elevated calcium levels (Prenzel et al., 2000) . Finally, the receptors interact with, and are modulated by, steroid hormone receptors and co-receptors. Erb-B3 was generally accepted to be kinase dead due to the lack of several key functional residues including the catalytic base aspartate, but a recent paper suggests that it nevertheless retains the ability to transphosphorylate its own intracellular domain (Shi et al., 2010) . In any event, it can certainly form a very active signalling complex with all other EGFR RTK, especially Erb-B2. There is a high degree of homology in the kinase domain of the four receptors (59-81%) but more divergence in the C-terminal domains (only 11-25% identity). In addition to cross-talk between members of the EGFR/Erb-B such as c-MET and IGF-1R, and it is possible that such alternative signalling pathways are linked to resistance to targeted therapies (Jin and Esteva, 2008) . Erb-B receptors also integrate signals from the extracellular microenvironment by forming macromolecular clusters with integrins and tetraspanins in specialised membrane microdomains (Alexi et al., 2011) 
Ligands
There are up to 13 recognised ligands of the EGFR family: EGF itself, heparin-binding (HB)-EGF, transforming growth factor (TGF) , amphiregulin (AREG) epiregulin (EREG), epigen (EPG), betacellulin (BTC) and neuregulins (NRG) 1-6 (also known as heregulins), which have multiple splice variants. EGF and TGF are the key EGFR binding ligands, BTC can bind and activate all receptors, and the NRGs have a preference for Erb-B3 and Erb-B4. All EGF family ligands exist as membrane-anchored precursors and are cleaved by metalloproteases (mainly ADAMs) resulting in ectodomain shedding and the release of soluble factors. The cleaved products, particularly of HB-EGF, have been implicated in transactivation of adjacent Erb-B receptors, and the remaining intracellular carboxyterminal fragments may have additional intracellular signalling functions (Higashiyama et al., 2008) . The EGFR ligand shedding factors, including cytokines which bind G-protein couple receptors, activating PKC and MAPK signalling pathways (in the so-called triple membrane-passing signal mechanism) or via Wnt ligands binding Fzd receptors. Uncleaved, membrane-bound ligands can also stimulate adjacent cells via a juxtacrine mechanism which may be particularly important in epithelial-stromal communication. There EGFR phosphorylation and dictate the duration of signalling events and divergent cellular responses. For example, TGF and AREG are more potent stimulators of motility and invasion than EGF. This is reportedly due to sustained activation of PLC and MAPK by the and degradation of EGFR.
Downstream signalling
Ligand binding induces conformational rearrangements of the receptors to expose the interaction loop, promoting association of both homodimers and heterodimers, followed by internalisation and/or phosphorylation events. The phosphorylated (activated) receptors act as docking points for a number of direct substrates patterns of binding partners, although each may be recruited to the mode of activation and the dimerisation partner (Schulze et al.
sponses to external stimuli in different microenvironmental contexts and the integration of stimuli into co-ordinated cellular functions.
tion (Schulze et al., 2005) . Interestingly, EGFR and Erb-B4, the only fully functional receptors (in contrast to functions in different cellular contexts in response to their preferred ligands (EGF family and NRGs respectively).
Erb-B3 is activated primarily by NRG-1 and -2 and is a strong activator of the PI3 kinase pathway, having six binding sites for the p85 regulatory subunit. The PI3 kinase pathway is a pivotal point in cell signalling (mainly via AKT and mTOR) regulating cell size, metabolism, survival and proliferation. Negative regulation of pro-apoptotic and growth inhibitory pathways is mediated via FOXO transcription factors and GSK3 . There are additional links to promotion of motility via Rac and Rho, and angiogenesis via activation of HIF-1 .
In summary, the major signalling pathways activated by EGFRErb-B receptors are mediated by PI3 kinase, Ras-Raf (MAPK), JNK, PLC and result in a plethora of biological functions. Although initially termed "growth" factors, the ligands induce not only cell proliferation but also alter adhesion and motility and protect against apoptosis at the cellular level, and promote invasion and angiogenesis at the physiological level. Given that these signalling systems are critical in development, it is not surprising that their activation should result in multiple co-ordinated cell-and tissue-level responses in normal cells, but these are subverted by overexpression/misregulation in pathological processes such as cancer.
Roles in normal breast development
Much of our understanding of the functions of the Erb-B family in development has come from rodent models. EGFR is of course best known as the epidermal growth factor receptor and is primarother three family members are important for the development and maintenance of the cardiovascular and nervous systems, but also play complementary roles in breast development. Most of the Erb-B family receptors and their ligands are expressed in the mammary gland at some time during development, maturation and involution (Fig. 1 ). The precise and co-ordinated roles of the receptors and their ligands are to some extent confounded by spatial and temporal complexities, a degree of redundancy, and many layers of regulation. Nevertheless, those functions that have been elucidated have proved informative for the better understanding of The mammary gland is an unusual organ in that most of its development occurs not in embryonic development, but at puberty, stimulated by steroid hormones. Interestingly, the rudimentary emdifferentiation are orchestrated by signals from the surrounding stroma; indeed mammary epithelial cells can be completely redirected (e.g. toward salivary gland morphology and function) by placing them in association with mesenchymal cells from different tissues.
The earliest phases of breast development are oestrogen independent. In adolescence, oestrogen and oestrogen receptor (ER) induce the next stage of branching, and in the adult progesterone ADAM17 null mice show the same developmental defects as those lacking TGF-, or HB-EGF, suggesting that this protease is primarily responsible for their processing and cleavage (Sahin et al., 2004) . Further evidence of its physiological importance in mammary development was provided by its appropriate localisation in the gland (although this was also the case for many other ADAMs). However, the reciprocal lack of its sole inhibitor (TIMP3) in TEBs suggests that ADAM17 would be active in areas of active ductal development.
The means by which EGFR-activated stromal cells induce mammary epithelial development has also been intensively studied but it still not fully elucidated. differentiation) it is likely that many simultaneous cellular responses are elicited. MT1-MMP (MMP14) is enriched in stroma surrounding TEBs and its activity, like that of ADAM17, would be enhanced by the local downregulation of TIMP3. MMP14 may stimulate ductal branching by activating MMP2 and degrading collagen 1. However it is membrane-bound and could defects in TEBs in Erb-B2 -/-mammary epithelium penetration into the fatpad, secondary to misregulation of matrix metalloproteinases, since branching morsecondary and tertiary branching. Another potential contributory mechanism is signalling via FGFR2 on mammary epithelial cells stimulated by stromal FGF10 providing both mitogenic stimuli and guidance cues for ductal development (Sternlicht and Sunnarborg, 2008) (Fig. 2) . (Sternlicht and Sunnarborg, 2008) (Fig. 2) .
since knock-out of either gene results in similar abnormalities in these processes.
Erb-B3 appears when mammary glands mature and Erb-B4 is only expressed during pregnancy and lactation. In Erb-B3-/-mice, there was a decrease in the size of TEBs but increases in branch density and the number of TEBs. This was associated with an increase in apoptosis but no change in cell proliferation rates in TEBs. The major signalling pathway activated by Erb-B3 in this context seems to be PI3 kinase (Stern, 2008) . Nrg3 polymorphisms can also result in abnormalities in rodent mammary gland development, also likely via activation of Erb-B3. Thus Erb-B3 plays a key role in regulating morphogenesis of mammary epithelium (Fig. 1) .
During pregnancy and lactation, Erb-B2, in association with its differentiation and milk protein production. Erb-B4 is essential for lobuloalveolar development and for maintaining lactation reportedly via Stat5a. The ligand(s) responsible for activating Erb-B4 in HRG1 has been implicated. Most of Erb-B4's functions in the mammary gland seem to be mediated by a soluble intracellular fragment (4ICD). This fragment can localise in mitochondria and nuclei, eliciting different functional responses in cells. The 180 kDa membrane-bound Erb-B4 is cleaved by ADAM17, releasing a 120 kDa ligand-binding ectodomain and an 80kDa transmembrane peptide (m80) with kinase activity (Blobel et al., 2009 ). The latter in many cancers, including breast, linked to a multiplicity of molecular mechanisms including epigenetic mechanisms, activating mutations of the receptors themselves or activation induced by autocrine/paracrine ligands. EGFR is other TKR, and also heterologous receptors such as GPCR via Src. Recently a novel mechanism of EGFR signalling has been suggested: EGFinduced translocation to the nucleus associated with p-Tyr-1068 and indirect binding to DNA via STAT3 enabling EGFR to act as a transcriptional regulator of genes such as cyclin D1 and iNOS -discussed in (Burness et al., 2010) .
Links to breast cancer
All of the four receptors are overexpressed to varying degrees in breast cancer, with their prominence being in rank order Erb-B2>EGFR>Erb-B3>Erb-B4. Many ligands, including NRG splice variants are also overexpressed, suggesting the possibility of autocrine signalling, although the combined measurement of EPG and NRG4 were the strongest predictors of relapse free interval and overall survival (McIntyre et al., 2010) .
EGFR
Many early reports of expression/overexpression of EGFR and its ligands in breast cancer and links to prognosis were contradictory as they were largely based on immunohistochemical data and did not necessarily address the activation state of the signalling pathway. More (Sternlicht and Sunnarborg, 2008) . fragment is released from the membrane by presenilin-dependent -secretase cleavage. Cleavage can be stimulated by ligand binding (generally HRG, HB-EGF or BTC) or simply in response to Erb-B4 overexpression.
interactions between stromal cells and mammary epithelial cells (MEC) during normal development. ADAM sheddases, regulated by oestrogens, release ligands such as AREG which stimulate EGFR on neighbouring stromal cells. Additional proteases (e.g MMP2 activated by MT1-MMP) release growth factors which reciprocally stimulate MECs to proliferate. MMPs are also required for ductal 'invasion' into the fat pad. Adapted from
Nuclear 4ICD in secretory mammary epithelium signalling via Stat5a is thought to be the major driver of lactation since Stat5a transcriptionally regulates -casein and whey acidic protein (WAP) promoters. The proposed mechanism is as follows: Erb-B4 when activated becomes phosphorylated at Y964, providing a docking site for Stat5a SH2 domains. The following regulated intra-membrane proteolysis (RIP) previously described results in liberation of the 4ICD-Stat5a complex and its translocation to the nucleus. It has been suggested that the 4ICD simply acts as a Stat5a chaperone, but may also serve as a regulator of transcription (Jones, 2008) or indeed have intrinsic independent transactivation activity. The 4ICD fragment also functions as a selective ER co-activator since it regulates expression of PGR, SDF-1 and Erb-B4 itself. This involves ER recruitment not to canonical ERE sites but to AP-1 sites in a complex with c-Jun (DeNardo et al., 2007) . In contrast, cytosolic 4ICD may have different functions, which may explain to breast cancer biology.
Mutations and mechanisms of activation
Deregulation of Erb-B signalling pathways has been described recent gene expression analyses and also functional studies have subsets (Foley et al., 2010) .
in some cases (e.g. metaplastic subtype) (Burness et al., 2010) breast cancers, a subset of triple negative breast cancers (TNBC; i.e. lacking ER, PGR or Erb-B2). TNBCs represent 10-17% of all breast cancers, are more common in certain non-Caucasian ethnic groups (e.g. those of African descent) and tend to occur at less than 50 years of age. These cancers are also generally of high grade and show distinct patterns of metastasis; notably visceral, liver and brain involvement leading to particularly poor prognosis (Dawson et al., 2009) . EGFR expression was found to be higher in patients with nodal or distant metastases than in those without (Sutton et al., 2010) . Also, TGF and NRG2 and the proteases responsible ER-cancers (suggesting autocrine signalling) whereas AREG is expressed in ER+ cancers and may rather promote paracrine activation via the stroma (Foley et al., 2010) . TNBC is particularly prevalent in women carrying a BRCA1 mutation and EGFR overexpression is found in 67% of BRCA1 related cancers vs ~ 18% of sporadic cancers. Using human mammary epithelial cell (hMEC) cultures it was shown that even partial suppression of BRCA1 function (using RNAi) could induce EGFR expression and an increase in EGFR+ cancer stem-like cells, suggesting that this receptor could provide a growth advantage at early stages of transformation. Treating (MMTV-Cre) BRCA1 p53 +/-increased the latency period before mammary tumours developed, although this was limited to ER-and not ER+ subtypes (Burga et al., 2011) . These data suggest that early intervention with EGFR BRCA1 mutation carriers in a preventive setting. However, in established cancers, clinical trials to date have not shown major responses in unselected patient populations (Burness et al., 2010) . majority of patients having disease in their lymph nodes and over one third with distant metastases at the time of diagnosis. It is of RhoC GTPase (resulting in a highly angiogenic phenotype) and a hyperactivated MAPK signalling path which has been linked to overexpression of EGFR and Erb-B2 (Van Laere et al., 2007) .
EGFR has also been implicated as a key player in the mitogenic and motogenic effects mediated by the HGF-c-MET signalling axis in breast cancer. HGF and/or c-MET expression increase with tumour progression and each is independently associated with poor prognosis. Cross-talk between these RTK has been identiand conversely EGFR ligands activating c-MET via intracellular signalling pathways. EGFR inhibitors have been shown to attenuate HGF-mediated proliferation, motility and invasion of several breast cancer cell lines in vitro.
Erb-B2
Neu chemically-induced neuroblastoma and shown to be similar to a it is associated with poor prognosis, although it is an early event occurring in over half of in situ carcinomas. Interestingly, an Erb-B2 subtype clearly emerged from a genetic analysis of breast cancer properties (Sorlie, 2004) . Breast cancers may express between 25-50 copies of the ERB-B gene resulting in up to 2 million receptors per cell. This differential provides a relatively tumour-selective therapeutic target, as levels are absent or low in most normal adult tissues. One exception is the heart, which may explain some of the cardiomyopathies seen with Erb-B targeted therapies, particularly when they were administered with anthracyclines, which is no longer a recommended combination (Procter et al., 2010) .
including increased sensitivity to doxorubicin (perhaps because the HER2 doxorubicin) and relative refractoriness to anti-endocrine agents (partly due to an inverse relationship between Erb-B2 and ER expression levels). It has been suggested that Erb-B2+ breast cancers may be especially prone to post-surgical recurrences due to their this could be prevented by trastuzumab. However, only a subset of Erb-B2+ breast cancers responds to trastuzumab, suggesting additional levels of complexity. Recently, more detailed analyses have revealed not only genetic heterogeneity within Erb-B2+ tumours, levels of hypoxia-regulated genes show characteristics of basal cancers, and those without behaved more like luminal cancers, showing that even oncogenic drivers such as Erb-B2 are susceptible to modulation by the host microenvironment (Gatza et al., 2011) .
Erb-B3
In mouse mammary carcinoma models induced by PyVMT or mutated or overexpressed neu, found in association with Erb-B2, again attesting to the effective lapatinib: response has been associated with inhibition of Erb-B3 and AKT phosphorylation. In contrast resistance has been linked with a de novo point mutation in Erb-B2. In a panel of six Erb-B2-overexpressing human tumour cell lines, Erb-B3 knockdown by RNAi was as effective as Erb-B2 knockdown at inhibiting proliferation in vitro, and xenograft tumour growth in vivo, whereas EGFR expression was dispensable. Preferential phosphorylation of Erb-B3 was also seen in Erb-B2+ human breast cancers, suggesting a pivotal role for Erb-B3 in Erb-B2-driven tumours (Stern, 2008) .
Erb-B3 is overexpressed in around 10% of breast cancers, must function solely as a key dimerisation partner, although it can become phosphorylated by other receptors. The phosphorylated form strongly activates the PI3 kinase pathway as it contains multiple binding sites for the p85 regulatory subunit. In some studies Erb-B3 expression seemed to correlate with ER positivity and was associated with longer overall survival. There is a stronger associacannot be excluded. There are thought to be important but poorly understood roles for nuclear localization and secreted isoforms such as p85 soluble Erb-B3, akin to the p95Erb-B2 ECD. The disparate results reported could also be related to the subcellular localisation of Erb-B3 and its activation status, which in turn are regulated by ligand availability.
Erb-B4
There are contradictory data on the role of Erb-B4 in breast cancer since both positive and negative associations with prognosis have been described; also the full-length and cleaved (4ICD) splice variants may have different functions (Sundvall et al., 2008) . It is reportedly associated with luminal A breast cancer subtypes (which have a better prognosis than other groups) perhaps linked to its role in differentiation. It is also generally associated with positive ER status and hence has been predicted to be oestrogen regulated. In support of this is the fact that its promoter contains three possible oestrogen response element half-sites and oestrogen recruits ER to one of these sites.
Inhibition of Erb-B4 expression can inhibit the proliferation of ER+ breast carcinoma cell lines, suggesting a growth promoting effect that is ER -dependent and reliant upon cross-talk between these two signalling pathways. Other Erb-B family members also show reciprocal interactions, with mechanisms that include phosphorylation of ER or its co-activators, linked to ER -induced upregulation of Erb-B ligands and a fostering of autocrine signalling loops. However, the Erb-B4 mechanism involving interactions between a Paradoxically, stimulation of ER+ breast cancer cells with Erb-B4 ligand, however, can result in cell death, even though it is also dependent on proteolytic release of 4ICD. It has been proposed that, since this activity is independent of nuclear localisation, it may be the result of 4ICD activity in the cytosol. 4ICD contains motifs similar to pro-apoptotic BH3 proteins and localises in mitochondria and the endoplasmic reticulum; also its anti-tumour activity is attenuated by the caspase inhibitor zVAD, suggesting that it is a bone apoptosis inducer. In support of this function, an association between cytosolic expression of 4ICD and apoptotic cells was noted in human breast cancers (Jones, 2008) . A unifying hypothesis to explain these disparate functions has been proposed whereby in early stages of breast cancer development, ligand (mainly HRG ) activation of Erb-B4 generates nuclear 4ICD. ER+ cells have a growth advantage and a 4ICD-dependent autocrine loop develops, shifting from a Stat5 co-activator of differentiation to an ER coactivator driving proliferation. At later stages both ER and Erb-B4 may be lost, perhaps being redundant in the face of additional even stronger oncogenic drivers (Jones, 2008) . These intriguing possibilities (and their therapeutic implications) are currently being actively investigated.
These varying associations between the Erb-B receptors and breast cancer biology are interesting as they may echo their contrasting roles in mammary gland development: promoting cell proliferation/'invasion' of ductal epithelial cells into the mammary fat in the case of EGFR/Erb-B2/3 and a function in epithelial differentiation for Erb-B4 (Stern, 2008) . It may be that subsets of precursor cells, trapped in that phenotype, unresponsive to normal regulatory cues.
Ligands and downstream signalling pathways in breast cancer
Given the importance of the ADAM17-AREG/TGF -EGFR axis in normal mammary development, it is not surprising that all of these elements -and those that they regulate such as additional proteases and growth factor signalling pathways -are misregulated in breast cancers. ADAM17, AREG and TGF with co-expression of TGF and EGFR being associated with particularly poor prognosis. Antisense suppression of AREG reduced the tumorigenicity of immortalised human mammary epithelial cells and prevented EGFR becoming activated in response to exogenous ligands .
In an interesting series of experiments with human mammary epithelial cells at different stages of transformation from immortalised -premaligant -tumorigenic, it was shown that progression was associated with upregulation of AREG and TGF , rendering them independent of exogenous EGF. In 3D cultures, reversion to a non-malignant phenotype was achieved by inhibitors of proteolytic activity or EGFR, suggesting an autocrine MMP/ADAM-dependent EGFR activation pathway. Similar effects were achieved by ADAM17 siRNA (Kenny and Bissell, 2007) , suggesting that this protease may be a good therapeutic target in EGFR-dependent breast cancers.
Angiogenesis, invasion and metastasis
and/or stimulate de novo angiogenesis in order to grow progressively. The newly formed vasculature is leaky and provides a ready conduit for haematogenous dissemination. One of the major angiogenic growth factors is VEGF, which is upregulated not only by hypoxia, but also via the Erb-B oncogenes, likely via the PI3K-AKT signalling pathway. Erb-B2 and EGFR overexpression tends to correlate with increased levels of VEGF A (and also lymphangiogenic cytokines VEGF C and D) and in some cases with higher microvessel density.
Hypoxia itself is a known adverse prognostic indicator, and many HIF-responsive genes (such as MMPs, CXCR4, c-MET, LOX) are implicated in angiogenesis and metastasis. In the case of the G-protein-coupled chemokine receptors such as CXCR4, and its ligand CXCL12/SDF-1 , their expression and activation has also been linked to site-selective metastasis. Erb-B2 and CXCR4 levels tend to correlate in breast cancers, and the former is reported to enhance CXCR4 expression and to inhibit ligand-induced degradation. Interestingly, inhibition of CXCR4 expression suppressed Erb-B2-mediated malignant potential suggesting a mechanistic linkage between the two signalling axes.
In order to metastasise, cells must detach from underlying exanchorage independent conditions, and demonstrate the ability to invade surrounding tissues and basement membranes. Invasion motility has also been described. An early manifestation of breast cancer is the ability of transformed but premalignant cells to proliferate within the ductal lumen, away from their natural ECM niches. Detachment usually induces downregulation of EGFR (and cell death) but this can be overcome by Erb-B2, which stabilises EGFR and 1 integrin via Erk-Sprouty2 signalling and a lowered (Grassian et al., 2011) . Erb-B2 and EGFR are also recognised as activating key signal-ling pathways promoting cell motility; indeed EGFR ligands are very potent chemotactic factors, stimulating rapid migration along concentration gradients. AIB1/SRC3 is associated with breast NRG-Erb-B2 mediated motility, co-operating with Erb-B2 to induce progression of DCIS to invasive ductal carcinoma. Erb-B2 reportedly selectively promotes MDA-MB-468 migration mediated by EGF via phosphorylation of tyr 1248 and a transient activation of PLC . Others have implicated Tyr 1227 and Shc-Memo signalling in response to HRG in T47D cells, although in both cases PLC was an important contributor. HRG enhances metastasis via PI3 kinase signalling, since mutation of its six YXXM PI3K p85-binding domains inhibited breast carcinoma cell motility, invasion, vascular intravasation and invasion (Smirnova et al., 2011) .
Overall, EGFR/Erb-B signalling has been linked to all aspects of metastasis: stimulation of angiogenesis, alterations in cell-cell and cell-matrix adhesion, upregulation of proteases and other key extravasation and organ-selective colonisation (Eccles, 2001) 
Organotropism and site selectivity of metastasis
The commonest site of breast cancer metastasis is the bone, and host cells that perpetuates tumour cell colonisation, metastasis development and bone destruction (Guise, 2010) . Although there Erb-B receptors (or their ligands) in bone metastases -and indeed Erb-B2 seems to be under-represented -there is good evidence of a role for ligand-activated proteases in the bone microenvironment (Foley et al., 2010) .
Seminal work by Massague's group deciphered the genetic determinants underlying key phases of metastasis in the MDA-MB-231 breast carcinoma model: escape from the primary tumour, extravasation and growth at secondary sites. Sublines with their key characteristics analysed. Osteoclast activity in the bone microenvironment is regulated by a balance between RANKL and osteoprotegerin (OPG). The presence of breast cancer cells upsets this balance, leading to a net increase in bone destruction via os- 3). There is now a growing appreciation that bone-marrow-derived mesenchymal stem cells (MSC) are recruited to the stroma of developing tumours and also contribute to formation of the tumour cell-derived TGF simulated release of angiogenic factors and induced breast carcinoma cell migration; another example of mutual Erb-mediated tumour-host interactions involved in tumour progression (De Luca et al., 2011) .
Dissemination to lymph nodes is a key factor in breast cancer staging, but increasingly identhe blood and in bone marrow aspirates is also being linked to poor prognosis. These cells when the primary tumour is negative) (Braun et al., 2001) . Such observations have led to the acceptance that dissemination may be a much earlier event than originally appreciated (Eccles and Paon, 2005) and that the Erb-B proteins, tumour cell escape, motility and dissemination. stimulate growth and invasion of the tumour (Kang et al., 2003) .
Ligands such as EGF or AREG shed by tumour cells activate EGFR-expressing osteoblasts to secrete less OPG; simultaneously autocrine stimulation releases PTHrP from tumour cells to the same end, and the osteoblasts in turn release EGFR ligands and perpetuate the cycle of monocyte-derived osteoclast activation via RANKL or MCP and thus bone destruction (Foley et al., 2010) . PTHrP has been recognised as one of the "metastasis virulence factors" within a bone metastasis gene signature. It transcriptionally regulates AREG and to a lesser extent TGF and HB-EGF, and may also increase ligand shedding via ADAM17. MMP1 and ADAMTS-1, additional members of the 11-gene signature, also increase AREG shedding and bone metastasis. Although MDA-MB-231 represents an ER negative breast cancer, since AREG is regulated by oestrogen, this pathway could be of more general whether EGFR inhibitors will have an impact, alone or in combination, against bone metastasis.
A degree of organotypic metastasis selection is determined by the ability of tumour cells to extravasate through the phenotypicallybarrier to tumour cell colonisation; however the lung endothelium has tight junctions and the blood-brain barrier (BBB) is even further specialised. EREG, together with COX-2, MMP-1 and ANGPTL4 has been linked to an enhanced capacity of breast tumour cells to extravasate in the lungs since together they can compromise the integrity of the pulmonary microvasculature. In contrast, HB-EGF, 2,6-sialyltransferase ST6GALNAC5 were strongly associated with breast cancer brain metastases (Bos et al., 2009) (Fig. 3) .
The predilection of breast cancers expressing Erb-B oncogenes to metastasise to the brain may also be due to the fact that their cognate ligands (NRGs) are neural growth factors. It has been shown experimentally that Erb-B2 overexpression increases the outgrowth of breast cancer cells in the brain, rather than the initial (Palmieri et al., 2007) . The co-association of CXCR4 and Erb-B2 may be linked to visceral metastases, and similarly cells overexpressing EGFR could respond to the high levels of ligands such as TGF and EREG in liver and lung (Eccles and Welch, 2007) (Fig. 3) .
Therapy targeting the EGFR/Erb-B family
EGFR and Erb-B2 have been the main receptors considered as targets for immunotherapeutic approaches in breast cancer, mainly via antibody-based therapies, but also in active immunisation and gene therapy protocols, as well as ligand-targeted toxin and antisense/RNAi approaches and anti-Erb-B2 vaccines (Ladjemi et al., 2010 ) (Table1; Fig. 4) .
A novel means of inhibiting Erb-B expression and function is via HSP90 chaperone inhibitors such as 17-AAG and NVP-AUY922. HSP90 levels correlate with poor prognosis in breast cancer and -pendent on HSP90 for its correct folding and cellular localisation. HSP72, a related chaperone, has also been shown to be essential for Erb-B2-driven oncogenesis in transgenic mouse models by 
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regulating senescence signalling pathways (Meng et al., 2011) . Other key client proteins are also important in breast tumour development (e.g. ER ) and progression, for example: AKT in cell survival and resistance to multiple agents; VEGF receptors in angiogenesis/lymphangiogenesis; FAK, Src and MET in invasion -to name but a few. HSP90 inhibitors induce depletion and proteasomal degradation of Erb-B2 and other client proteins in vitro and in vivo, resulting in potent antitumour and antiangiogenic activity in preclinical tumour models (Eccles et al., 2008) , most notably in ER +/Erb-B2+ BT474 xenografts. Recent clinical trial data in MBC where patients had progressed on trastuzumab are very promising (Modi et al., 2011) . In preclinical and clinical stud-. In preclinical and clinical studies, trastuzumab labelled with positron-emitting isotopes has also been used to monitor responses as described later in this review.
Inhibiting ligand binding/dimerisation
The anti-EGFR antibody cetuximab has been tested in combination with a variety of standard chemotherapeutic agents in breast fact that Erb-B2 positive tumours have a predilection for colonising the brain and because antibodies fail to cross the BBB effectively.
Pertuzumab is another humanised antibody that inhibits Erb-B2 heterodimerisation with other family members by binding to the dimerisation loop of the former (i.e a different site from trastuzumab). It has shown some promise in Erb-B2+ breast and ovarian cancer patients and is also being evaluated in combination with trastuzumab and chemotherapy (CLEOPATRA trial) (Baselga and Swain, 2010) . In general, Erb-B2 targeted therapies are only effective in cancers -mine those eligible (e.g. HercepTest or Oncotype Dx). Antibodies to Erb-B2 have also been employed to measure expression levels in tumours and also to monitor responses to therapy using positron emission tomography (PET) or Erb-B2-targeted nanoparticles in MRI approaches, since they report non-invasively on the level of membrane-exposed receptor (Capala and Bouchelouche, 2010) . Similarly, ELISA or dot-blot assays can be performed on plasma samples to monitor the levels of Erb-B2 ECD and also reportedly correlate with tumour levels in several studies.
Advances in antibody-based therapies include the targeting of toxicity. Cetuximab is a chimeric IgG1, whereas panitumumab is a fully human IgG2 anti-EGFR monoclonal antibody in breast cancer (Burness et al., 2010) .
Trastuzumab, a humanised anti-Erb-B2 monoclonal antibody targeting the juxtamembrane region of the extracellular domain, has been more successful in clinical trials, particularly in combination with standard chemotherapy and in the adjuvant setting (Goel et al., 2011) . This sensitisation to chemotherapy may involve downregulation of Mcl-1, an antiapoptotic protein and/or activation of PTEN which dephosphorylates AKT (a key survival signal) thereby promoting cell death. Trastuzumab is reportedly most active in tumours driven by Erb-B2 homodimers and is also effective in combination with antiendocrine therapies in ER+ tumours. Given the many key cellular functions activated downstream of Erb-B signalling, it is not surprising that trastuzumab (and other Erb-B-targeted therapies) also inhibit angiogenesis, which could contribute indirectly to tumour responses. Combinations of trastuzumab with bevacizumab, an antibody targeting the major angiogenic cytokine (VEGF) are also being trialled.
In addition to direct inhibition of Erb-B2 function, e.g. by promoting its internalisation and degradation, trastuzumab can promote antibody-directed cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells. Interestingly (but unfortunately) an increase in the incidence of brain metastases has been observed in patients treated prodrug activating enzymes or nanoparticles carrying cytotoxic payloads (Colombo et al., 2010) . Recently, complexes of a com-. Recently, complexes of a compact human anti-Erb-B2 antibody and cytotoxic human pancreatic RNase have shown promise in vitro and in vivo in a rodent breast tumour model (Borriello et al., 2011) . In experimental systems, it has been shown that using combinations of anti-Erb-B2 antibodies recognising different epitopes are more effective at inhibiting ligand-mediated invasion than single agents.
Inhibiting kinase activity
Several reversible and irreversible SMTKI with varying degrees of selectivity have been developed. These small molecule agents compete with ATP binding in the kinase domain of the receptor and inhibit downstream signalling. The most well known are the EGFR inhibitor lapatinib and the more recently developed irreversible inhibitor afatinib.
in breast cancer, even in triple negative cases which often have high levels of EGFR. Several trials are underway where EGFR TKI are used in combination with other cytotoxic or molecularly targeted agents.
Lapatinib binds the ATP-binding pocket of both EGFR and Erbor rapid development of resistance to monotherapies. Unlike trastuzumab, activation of the PI3K pathway does not seem to both cytotoxic and molecularly targeted agents. Combination with trastuzumab improved median progression-free survival and reduced the risk of disease progression in a phase III trial of heavily pre-treated patients and it has also been approved for use in those who have failed trastuzumab. Most responses have been seen in triple negative or EGFR-positive cancers (Burness et al., 2010) . Neratinib is another orally active agent which irreversibly inhibits the kinase activity of EGFR, Erb-B2 and Erb-B4 which has shown promise in previously untreated and also trastuzumab-resistant breast cancers (Colombo et al., 2010) . It is also being trialled in combination with paclitaxel, capecitebine and vinorelbine.
Links between Erb-B signalling and resistance to therapy
EGFR activation has been linked to resistance to the antiendocrine agent tamoxifen, possibly via phosphorylation of AIB1, an ER co-activator which can result in mitogenic (rather than inhibitory) activity. Phosphorylation of ER (which can be achieved by several upstream kinases including Erb-B2) can also lead to oestrogen-independent transcription of ER targets, also resulting in resistance to tamoxifen. There is cross talk between ER , c-Src, EGFR, and STAT5b in ER+ breast cancer cells and increased EGFR and c-Src signaling is associated with tamoxifen resistance. Constitutively active STAT5b increased DNA synthesis and conferred tamoxifen resistance in ER+ human breast carcinoma cell lines. Cells exposed to a pure anti-oestrogen (fulvestrant) acand phosphorylation of EGFR and Erb-B2, together with TGF and AREG expression. More recently, fulvestrant has also been shown to upregulate Erb-B3 and/or Erb-B4 and to sensitise cells to NRG 1 (Hutcheson et al., 2011) . It is possible, therefore, that mito-. It is possible, therefore, that mitogenic autocrine signalling via any or all of the Erb-B receptors may subsume the role of oestrogen during breast cancer progression.
EGFR activation stimulates signalling via AKT and ERK, and has been linked to multidrug resistance via upregulation of MRP-1,3,5 and 7. Erb-B3 (and also Erb-B4) has also been linked to resistance to anti-endocrine therapy (Sutherland, 2011) and to paclitaxel, reportedly by upregulating survivin via the PI3K-AKTmTOR pathway. Amphiregulin expression has been associated with resistance to cisplatin in MCF7 cells and in patients via enhanced EGFR, AKT and ERK1 activation. EGFR and Erb-B2 activation may also be involved with resistance to radiotherapy, since both are upregulated/activated following exposure to ionising radiation. targeted therapies have been described, including subversion of trastuzumab binding to Erb-B2 by shed p95 ECD fragments (Ar- (Arribas et al., 2011) ; a switch to alternative signaling via other Erb-B family members (notably Erb-B3), alternative RTK such as c-MET, -ments (e.g. PI3 kinase-AKT-FOX1A) for example via loss of PTEN or by PIK3CA mutations. (Garrett and Arteaga, 2011) . In the early days, the development of host antibodies against the therapeutic antibody could neutralise their activity upon repeat administration. However this has now largely been overcome by the development of humanised (or fully human) therapeutic antibodies.
In addition, there is evidence of primary resistance (or lack of sensitivity) in many patients, in spite of the fact that their tumours overexpress the target receptor, although the reasons for this -which are likely to be many and various -are less well understood. One mechanism may involve negative feedback loops in cases where trastuzumab fails to abolish Erb-B2 phosphorylation. This may occur due to trans-phosphorylation by other Erb-B receptors, following an AKT-dependent ADAM17-mediated release of Erb-B ligands (Gijsen et al., 2010) a common mediator of multiple trastuzumab resistance pathways de novo trastuzumab-resistant cells, involving dephosphorylation by PTEN. Increased c-SRC activation conferred resistance in breast cancer cells and correlated with trastuzumab refractoriness in patients. Targeting c-SRC re-sensitized cells to trastuzumab and eliminated trastuzumab-resistant tumours in vivo, suggesting a potential clinical application of this strategy (Zhang et al., 2011) .
Molecular mechanisms of resistance to small molecule inhibitors generally differ from those linked to refractoriness to antibody therapy. In the former case, mutations in the kinase domain of in the latter case, as described above, downregulation of the primary molecular target, a shift to non-inhibitable dimers (such as Erb-B2-IGF1R) or a short-circuit of the downstream signalling pathways is more common. Other reported resistance mechanisms include a mutation in exon 21 of the HER2 gene that encodes a MUC4, a membrane-bound glycoprotein which binds Erb-B2 and can compete with trastuzumab binding.
Future strategies will need to include rational combinations of therapeutic agents to overcome (or pre-empt) resistance. Research laboratories developing new targeted agents are deliberately future likely escape mechanisms of cancers in the clinic. These cells are then subjected to microarray or to proteomic analysis to uncover the mechanisms of resistance. If this reveals a mutated target (as in the case of EGFR), then screens can be performed to identify new compounds which can bind the altered conformation; agents or siRNA libraries can be used to identify new vulnerabilities (Achilles' heels) in the resistant cells which may be exploitable as targets. One good example is the multikinase inhibitor dasatinib, which shows synergistic anti-proliferative activity with trastuzumab in Erb-B2 expressing BT474 human breast carcinoma cells both in vitro and in vivo (Seoane et al., 2010) . Since one of the kinase targets of dasatinib is c-SRC, this protocol may also help to prevent development of resistance as outlined in the previous section.
Cancer stem-like cells (CSC)
Cells which express one or more supposed markers of stem cells (e.g. CD44 + /CD24
-ALDH1 + and with their phenotypic characteristics (self-renewal capacity, anchorage-independent growth, pluripotency) have been isolated from mammary glands and breast cancers. It has been proposed that such cells may represent the true seeds of cancer, contributing to drug resistance (due to expres-CSC may be endocrine resistant because they express low levels of ER clonogenicity of CSC derived from cancers and DCIS in soft agar, and overexpression of Erb-B2 in MEC increases the proportion of cells with CSC properties. Normal breast epithelial stem cells are highly dependent on EGFR and other RTK, raising the possibility that their increased expression in endocrine-resistant breast endocrine therapies. Several studies show that breast CSCs are ER +/EGFR+/Erb-B2+, supporting this view (O'Brien et al., 2011) . These observations suggest that Erb-B2 and/or EGFR inhibitors could target the CSC population, and indeed one small study with of CD44+/CD24-cells in breast cancer biopsies (Schmidt, 2008) . perhaps shed early in cancer progression, may remain dormant and refractory to therapy until reactivated, when they may contribute to treatment relapse and metastasis. There is no doubt that we will need to pay more attention to the genotypic phenotypic properties of pre-existing micrometastases if we are ever to provide robust and sustained control of disseminated breast cancer.
